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(o the Editor: Infarct size is a major determinant of mortality after
cute myocardial infarction (AMI) (1). Although timely reperfu-
ion of the ischemic myocardium in patients with ST-segment
levation myocardial infarction (STEMI) is the most effective way
o limit infarct size, reperfusion itself may cause damage, which is
nown as reperfusion injury (2). Animal data suggest that much of
he apoptosis that occurs during occlusion is augmented during
eperfusion. Although animal studies and, to a lesser extent,
uman investigations have suggested the presence of cardiac
yocyte apoptosis after AMI, more direct evidence of apoptosis in
umans during the acute phase of myocardial infarction (MI) is
acking.
In the present study, we used an enzyme-linked immunosorbent
ssay to determine the serum level of a cleaved p17 fragment (p17)
f caspase-3, the end effector caspase for apoptosis (3), in patients
ith STEMI.
We studied 27 consecutive patients undergoing primary percu-
aneous coronary intervention (PCI) for acute STEMI with a
oor-to-balloon time 90 min from December 2007 to January
010 at the University of Connecticut Health Center. Informed
onsent and protocol were approved by institutional review board
t our institution.
We measured caspase-3 with a commercial sandwich ELISA
ssay (PathScan Cleaved Caspase-3 [Asp175] Sandwich ELISA
it, Cell Signaling Technology, Beverly, Massachusetts). The
mount of p17 was determined by analysis of optical density at 450
m (OD450) using a Multi-Detection Microplate Reader (Biotek,
odel Synergy 2, Winooski, Vermont). The p17 peptide levels
ere linearly related to the amount of apoptotic HeLa cell lysates
fter staurosporine (1 M) exposure for 3 h at 37°C; serum p17
D450 was in the linear range.
The p17 levels were measured at least twice 8 h apart during the
nitial 24 h, and the peak level was determined as the higher of the
MI values. A subsequent determination was made 88  29.3
ays ( SE) after the AMI and is considered the post-MI value.
ardiac troponin I (cTnI) was determined by the Access AccuTnI
ssay (Beckman Coulter, Brea, California) and creatine kinase
CK)-MB determined by the Access CK-MB assay using Beck-
an DXI 800 (Beckman Coulter) every 8 h for 24 to 36 h with the
9th percentile value as the upper limit.
Given that cTnI, CK, CK-MB, and p17 values are not normally
istributed, nonparametric testing was used with a 2-sided p value
0.05 as significant.
All patients had occluded infarct-related arteries (Thrombolysis
n Myocardial Infarction flow grade 0 or 1). Post-PCI Thrombol-
sis In Myocardial Infarction flow grade was 3 in 89% of patients
nd grade 2 for the remaining patients. Age was 56.9  10.6 years
 SD) with 93% males. Left ventricular ejection fraction, by leftentriculogram (n  23) or echocardiogram (n  4), was 50.0 
.1% ( SD).
The cleaved caspase-3 p17 peptide was shown to escape
poptotic HeLa cells by being detectable in extracellular medium
fter induction of apoptosis, supporting the concept that p17
eptide can escape into circulation from cells in patients. The
orrelation of p17 values in a group of 50 healthy control subjects
epeated on 2 consecutive days was 0.522, p  0.0001 (Spearman,
edian of 0.037 with interquartile range [IQR] 0.030 to 0.043 on
ay 1 compared with a median of 0.039 with IQR 0.033 to 0.046
n day 2).
The peak serum p17 peptide level during AMI was higher than
he late post-MI serum level in 21 subjects in whom samples were
vailable during both phases (peak median OD450 of 0.080 with
QR 0.050 to 0.091 vs. post-median OD450 of 0.052 with IQR:
.034 to 0.072 respectively, p  0.0016, Wilcoxon signed-rank
est) (Fig. 1). Compared with healthy subjects, the peak AMI p17
evel (median of 0.080 with IQR: 0.050 to 0.091) was nearly 4-fold
igher than that in healthy subjects (median of 0.041 with IQR:
.034 to 0.050, n  167 subjects, Mann-Whitney U test, p 
.0001). The late post-MI p17 peptide level (median of 0.052 with
QR: 0.034 to 0.073) was also higher than that of healthy subjects
p  0.016), consistent with persistent apoptosis after AMI.
Figure 1 Caspase-3 p17 Peptide Levels During and After Acute STEMI
Serum samples were obtained from patients with ST-segment elevation myo-
cardial infarction (STEMI) and from healthy subjects and p17 peptide levels
measured as described in the Methods section. The peak level (n  27) during
the acute event, the post-myocardial infarction (MI) level (n  21), and the
level from healthy subjects (n  167) were presented as medians and inter-
quartile values. p  0.05 peak versus post-MI, Wilcoxon signed-rank test; p 
0.05 healthy versus peak or post-MI, Mann-Whitney U test.
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January 11, 2011:220–2In all subjects, the peak p17 peptide level occurred after PCI and
as positively correlated with the peak cTnI (r  0.48, p  0.011)
nd peak CK-MB (r  0.56, p  0.002, Spearman for all) levels.
he correlations were not tight, suggesting that both necrosis and
poptosis play a role in determining infarct size. The use of this
ovel assay for the first time sets the stage to investigate this critical
alance. The rise and fall of p17 peptide and its correlation with
eak cTnI and CK-MB suggest that serum p17 likely came from
njured myocardium. A calpain (4) and stretch-mediated (5)
yocyte apoptosis may have also contributed to the serum p17
evel.
Limitations include the lack of concurrent myocyte evidence of
poptosis and unknown p17 release kinetics. Designing therapies
o inhibit apoptosis may provide benefit to STEMI patients.
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Circulation 1993;87 Suppl VII:22–7.Letters to the Editoryocardial Salvage Index and
nfarct Size Represent Related
ut Distinct Components of
cute ST-Segment Elevation
yocardial Infarction
ne of the conclusions of Eitel et al. (1), that the myocardial salvage
ndex (MSI) assessed by cardiac magnetic resonance is the strongest
nverse correlate of major adverse cardiac events and mortality at
-month follow up (compared with infarct size [IS] alone measured in
he acute phase by late gadolinium enhancement by cardiovascular
agnetic resonance), is not supported by the data presented.
Inspection of the receiver-operating characteristic curves reveals
hat the predictive value of IS is similar to that indicated by the
SI (area under the curve: 0.791 vs. 0.803), and I suspect that it
ould be confirmed to be nonsignificant by appropriate statistical
nalysis comparing the 2 variables, which was not performed. This
s also expected from the large body of clinical evidence accumu-
ated thus far that final IS and consequently extent left ventricular
ysfunction determine the major adverse cardiac events and mor-
ality resultant from acute ST-segment elevation myocardial in-
arction (ASTEMI), as demonstrated by Larose et al. (2) in the
ame issue of the Journal, regardless of the extent of the MSI.
hus, if a large infarct was reperfused optimally with a large MSInd mortality would be similar to those of a small infarct
eperfused suboptimally with a small MSI but still a small final IS.
his is important because IS measurement (but not MSI) can be
imilarly accomplished by delayed contrast enhancement com-
uted tomography myocardial perfusion imaging with similar
ccuracy (from preliminary studies) (3) and myocardial contrast
chocardiography. Hence, this important prognostic variable could
ecome more rapidly and widely available clinically.
Their other conclusion that MSI determined by cardiac mag-
etic resonance provides the best clinical investigative tool to
easure success of therapies to limit IS in ASTEMI is of course
ntirely valid. More important, comparing the curve depicting the
elationship between the time to reperfusion and the MSI (that
hey have elegantly demonstrated) in control and treatment groups
s uniquely able to measure IS reduction in humans by therapeutic
easures to reduce reperfusion injury because this methodology
ontrols for the critical time to reperfusion variable in clinical
esearch in ASTEMI, which is the major determinant of MSI and
ence final IS. IS measurement alone in this research area would
e clearly inadequate. MSI by itself would be an excellent and
omprehensive measure of the effectiveness of an ASTEMI
eperfusion program superior to door-to-balloon time.
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